A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Inclusion Criteria:

• Have histologically or cytologically confirmed, advanced or metastatic non-smallcell lung cancer (NSCLC), characterized by either epidermal growth factor receptor (EGFR) Exon 19 deletion (Exon 19del) or Exon 21 leucine 858 to arginine substitution (Exon 21 L858R) mutation by an Food and Drug Administration (FDA)-approved or othervalidated test of either circulating tumor deoxyribonucleic acid (ctDNA) or tumortissue in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United Started [US]) or an accredited local laboratory (sites outsideof the US)

• Have progressed on or after osimertinib (or another approved 3rd generationepidermal growth factor receptor [EGFR] tyrosine kinase inhibitor [TKI]) andplatinum-based chemotherapy (irrespective of order). a) The 3rd generation EGFR TKImust have been administered as the first EGFR TKI for metastatic disease or as thesecond TKI after prior treatment with first- or second-generation EGFR TKI inparticipants with metastatic EGFR T790M mutation positive NSCLC. b) Participants whodecline or are otherwise ineligible for chemotherapy may be enrolled afterdiscussion with the medical monitor. c) Any adjuvant or neoadjuvant treatment,whether with a 3rd generation EGFR TKI or platinum based chemotherapy, would counttowards the prior treatment requirement if the participant experienced disease

• Have at least 1 measurable lesion, according to response evaluation criteria insolid tumors (RECIST) version 1.1

• Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1

• Any toxicities from prior anticancer therapy must have resolved to commonterminology criteria for adverse events (CTCAE) Version 5.0 Grade 1 or baselinelevel (except for alopecia [any grade], Grade less than or equal to (<=) 2peripheral neuropathy, and Grade <=2 hypothyroidism stable on hormone replacement)

Exclusion Criteria:

• Participant has received cytotoxic, investigational, or targeted therapies beyondone regimen of platinum-based chemotherapy and EGFR inhibitors

• Participant has received radiotherapy for palliative purposes less than 7 days priorto randomization

• Participant has symptomatic or progressive brain metastases

• Participant has leptomeningeal disease, or participant has spinal cord compressionnot definitively treated with surgery or radiation

• Participant has uncontrolled tumor-related pain

• Participant has a medical history of interstitial lung disease (ILD), includingdrug-induced ILD or radiation pneumonitis